2seventy Expects Q3 Abecma US Revenue Growth Of Approximately 30% From Q2 Revenue Of $54M
Portfolio Pulse from Benzinga Newsdesk
2seventy anticipates a 30% increase in Q3 US revenue for Abecma from Q2's $54M, with strong demand indicated by double-digit growth in new patients. The company is focused on sustaining Abecma's success into 2024.
September 25, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
2seventy expects a 30% increase in Q3 US revenue for Abecma, indicating strong market demand and potential positive impact on TSVT's financial performance.
The projected 30% revenue growth for Abecma in Q3 suggests strong market demand and could lead to a positive short-term impact on TSVT's stock price. The company's commitment to sustaining this growth into 2024 further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100